FimmCyte and Richter Collaborate on Endometriosis Breakthrough – Startupticker.ch
Startupticker.ch shared a post on LinkedIn։
“FimmCyte, a femtech company developing new treatments for endometriosis, has entered into a research collaboration and option-to-license agreement with Richter, a leading Hungarian pharmaceutical company, to advance research on its lead clinical candidate, FMC2. The parties have fully negotiated a definitive, exclusive and worldwide license agreement for the future development and commercialization of the antibody. FimmCyte will be eligible to receive development and commercial milestone payments, together with tiered royalties on net sales, as provided under the pre-agreed license agreement.
More about FimmCyte, its clinical candidate and the collaboration in our article․”

Stay updated on all scientific advances in the field of fertility with Fertility News.
-
May 29, 2026, 19:40The Great Egg Escape: Understanding Premature Ovulation in IVF – Fertility Plus
-
May 29, 2026, 19:38Devyanshi Dixit: Call for Abstract for GFWH 2026
-
May 29, 2026, 19:35Tom Holland: Advancing Robotic Surgery Skills at the T400 Course in Strasbourg
-
May 29, 2026, 19:33Silpi Saikia: Not Every Successful Blastocyst Comes From an Easy Case!
-
May 29, 2026, 19:31Register Now and Secure Your Spot at ASRM 2026 – ASRM
-
May 29, 2026, 19:29Sonam Jain: The Real Driver of IVF Conversion Is Patient Trust
-
May 29, 2026, 19:26Mediterranean Diet Before IVF Increases Successful Pregnancies by 40%! – Fertility Plus
-
May 29, 2026, 19:24Melanie Norton: Excited to Begin My Robotics Fellowship at UCLH
-
May 29, 2026, 19:22A Step Forward in Non-Invasive Diagnosis of Endometriosis – The Lancet Medical Imaging and Theranostics
